Literature DB >> 12409717

Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis.

Gamze Ayata1, Sarathehandra Ithamukkala, Heidi Sapp, Beth H Shaz, Tom P Brien, Helen H Wang, Donald A Antonioli, Francis A Farraye, Robert D Odze.   

Abstract

Collagenous colitis (CC) and lymphocytic colitis (LC) are clinical syndromes characterized by the presence of chronic watery diarrhea, few or no endoscopic abnormalities and biopsies that typically show normal crypt architecture, increased mononuclear inflammation in the lamina propria, absence of neutrophils, and increased intraepithelial lymphocytes. Patients with CC also have a thickened subepithelial collagen layer. We have noted, anecdotally, that biopsy specimens from some patients with CC or LC contain certain histologic features, such as Paneth cell metaplasia (PM), that are normally seen in inflammatory bowel disease (IBD), or other types of healed colitis, and thus may cause diagnostic difficulty. Therefore, the purpose of this study was to evaluate the prevalence and significance of IBD-like morphologic features in colonic mucosal biopsies from patients with CC or LC. Five hundred thirty-one routinely processed hematoxylin and eosin-stained colonic mucosal biopsies from 150 patients with clinically, endoscopically, and histologically confirmed CC (79 patients, male/female ratio: 14/65, mean age: 60 yr) or LC (71 patients, male/female ratio: 13/58, mean age: 55 yr) were evaluated in a blinded fashion for a variety of histologic features, including active crypt inflammation (cryptitis +/- crypt abscess), surface ulceration, Paneth cell metaplasia, crypt architectural irregularity, number of intraepithelial lymphocytes, and thickness of the subepithelial collagen layer (CC only). The results were compared between CC and LC and correlated with the clinical and endoscopic data. None of the patients had or developed IBD during the study period. Active crypt inflammation was a common finding in both groups, seen in 24 of 79 CC patients (30%) and 27 of 71 LC patients (38%). Surface ulceration was not seen in any of the LC biopsies but was present in 2 of 79 (2.5%) CC patients. Paneth cell metaplasia was frequent in both groups and significantly more common in CC compared with LC patients. Forty-four percent of CC patients, but only 9 of 63 (14%) of LC patients had Paneth cell metaplasia (p <0.001). Crypt architectural irregularity, although rare, was present in 6 of 79 patients with CC (7.6%) and 3 of 71 (4.2%) patients with LC. In patients with CC, the presence of Paneth cell metaplasia was associated with more severe disease characterized by the presence of abdominal pain (p <0.001) and a higher frequency of bowel movements (>3 bowel movements/day) (p = 0.06). Also, active crypt inflammation correlated with antibiotic use at the time of clinical presentation (p = 0.04) and was present in the only two patients who had positive stool cultures (one each for and ). However, none of the other histologic findings correlated with any of the other clinical or endoscopic features, such as type of symptoms, stool consistency, type of medical treatment, associated autoimmune diseases or outcome (complete, partial, or no resolution) in either group of patients. Pathologists should be aware that some histologic features normally associated with IBD such as crypt irregularity and neutrophilic cryptitis and crypt abscesses are not uncommon in patients with CC or LC and that the presence of one or more of these features should not necessarily be interpreted as evidence against either of these diagnoses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409717     DOI: 10.1097/00000478-200211000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

Review 1.  Lymphocytic and collagenous colitis: an overview of so-called microscopic colitis.

Authors:  Runjan Chetty; Dhirendra Govender
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

Review 2.  Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded.

Authors:  Tze S Khor; Hiroshi Fujita; Koji Nagata; Michio Shimizu; Gregory Y Lauwers
Journal:  J Gastroenterol       Date:  2012-02-10       Impact factor: 7.527

Review 3.  Current Approach to the Evaluation and Management of Microscopic Colitis.

Authors:  Thomas G Cotter; Darrell S Pardi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

4.  Cord colitis syndrome: a cause of granulomatous inflammation in the upper and lower gastrointestinal tract.

Authors:  Nitin K Gupta; Ricard Masia
Journal:  Am J Surg Pathol       Date:  2013-07       Impact factor: 6.394

5.  Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis.

Authors:  Harry Sokol; Nadia Vasquez; Nadia Hoyeau-Idrissi; Philippe Seksik; Laurent Beaugerie; Anne Lavergne-Slove; Philippe Pochart; Philippe Marteau
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

6.  Th1 Pathway: The Missing Link Between Inflammatory Bowel Disease and Microscopic Colitis?

Authors:  Anna Carrasco; Fernando Fernández-Bañares
Journal:  Dig Dis Sci       Date:  2017-10       Impact factor: 3.199

7.  NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis.

Authors:  Ahmed Madisch; Stephan Hellmig; Stephan Schreiber; Birgit Bethke; Manfred Stolte; Stephan Miehlke
Journal:  Int J Colorectal Dis       Date:  2006-06-28       Impact factor: 2.571

Review 8.  Biopsy diagnosis of colitis: an algorithmic approach.

Authors:  Deepa T Patil; Robert D Odze
Journal:  Virchows Arch       Date:  2017-11-25       Impact factor: 4.064

9.  Pseudomembranous collagenous colitis: an unusual cause of chronic diarrhoea.

Authors:  Ayisha Mehtab Khan-Kheil; Benjamin Disney; Ernie Ruban; Gordon Wood
Journal:  BMJ Case Rep       Date:  2014-02-13

10.  Endoscopic Evaluation of Microscopic Colitis.

Authors:  Stephen J Bickston
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.